BioSpace News Archive

Trevi announced that management will host a conference call and live audio webcast on Thursday, March 17, 2022, at 4:30 p.m. ET, to provide a corporate update and review the Company’s financial results for the fourth quarter and full year ended December 31, 2021.

Total net sales of $67.4 million for the full year, up 14% from the prior year, with $56.7 million from Tru Niagen® and gross margin of 61.5%.

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for the fourth quarter and year-end 2021 and provided a business update.

Acorda Therapeutics, Inc. reported its financial results for the fourth quarter and full year ended December 31, 2021.

MaxCyte, Inc., a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, announced Cenk Sumen, Ph.D., as Chief Scientific Officer.

GT Biopharma, Inc. (NASDAQ: GTBP), presented preclinical data demonstrating its novel TriKE driving NK cell immunotherapy against non-small cell lung cancer (NSCLC) in the hypoxic solid tumor microenvironment at ESMO’s Targeted Anticancer Therapies Congress (TAT).

Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted fourteen new employees options to purchase a total of 61,000 shares of the Company’s common stock at an exercise price per share of $33.03 which was the closing price on March 8, 2022, and restricted stock units to acquire a total of 30,500 shares of the Company’s common stock.

Maravai LifeSciences, Inc., a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conferences during the month of March.

Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH), announced today its management team will participate in the 32nd Annual Oppenheimer Healthcare Conference on Tuesday, March 15, 2022 at 8:00 AM ET.

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that company leadership is scheduled to participate in a fireside chat at the 32nd Annual Oppenheimer Healthcare Conference.